140 related articles for article (PubMed ID: 9196146)
1. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.
Chan DW; Beveridge RA; Muss H; Fritsche HA; Hortobagyi G; Theriault R; Kiang D; Kennedy BJ; Evelegh M
J Clin Oncol; 1997 Jun; 15(6):2322-8. PubMed ID: 9196146
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA.
Lynch DM; Rogers PE; Love JC; Salkas MJ; Skarphol KA; Gross ME; Lu MG; Petrides VH; Bruzek DJ; Cox JL; Jones KA; Kelley CA; Chan DW
Tumour Biol; 1998; 19(6):421-38. PubMed ID: 9817970
[TBL] [Abstract][Full Text] [Related]
4. Quantification of MUC1 in breast cancer patients. A method comparison study.
Bon GG; van Kamp GJ; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):67-75. PubMed ID: 10221613
[TBL] [Abstract][Full Text] [Related]
5. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
6. Circulating CA 549 and other associated antigens in breast cancer patients.
Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
[TBL] [Abstract][Full Text] [Related]
7. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
8. CEA and CA 15-3 in primary and recurrent breast cancer.
O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
[TBL] [Abstract][Full Text] [Related]
10. New markers for breast carcinoma-associated antigen in comparison with CA 15-3.
van Dalen A
Anticancer Res; 1996; 16(4B):2339-43. PubMed ID: 8694566
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
12. [CA 15.3 and early diagnosis of recurrence in breast cancer].
Basuyau JP; Brunelle P; Charrot P; Chevallier B; Delapierre F; Graic Y; Julien JP; Veyret C
Bull Cancer; 1993 Mar; 80(3):213-8. PubMed ID: 8173173
[TBL] [Abstract][Full Text] [Related]
13. A new biomarker in monitoring breast cancer: CA 549.
Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
[TBL] [Abstract][Full Text] [Related]
14. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
15. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
Bartel U; Johannsen B; Reiss H; Elling D
Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
[TBL] [Abstract][Full Text] [Related]
16. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.
Bombardieri E; Pizzichetta M; Veronesi P; Seregni E; Bogni A; Maffioli L; Jotti GS; Bassetto MA; Zurrida S; Costa A
Eur J Cancer; 1992; 29A(1):144-6. PubMed ID: 1445733
[TBL] [Abstract][Full Text] [Related]
17. CA 15-3 in patients with locoregional and metastatic breast carcinoma.
Geraghty JG; Coveney EC; Sherry F; O'Higgins NJ; Duffy MJ
Cancer; 1992 Dec; 70(12):2831-4. PubMed ID: 1451063
[TBL] [Abstract][Full Text] [Related]
18. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
Fritsche E; Benz J
Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
[TBL] [Abstract][Full Text] [Related]
19. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P
Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
